34 related articles for article (PubMed ID: 16205624)
1. Rho-associated kinase inhibitors: a novel glaucoma therapy.
Inoue T; Tanihara H
Prog Retin Eye Res; 2013 Nov; 37():1-12. PubMed ID: 23770081
[TBL] [Abstract][Full Text] [Related]
2. Metabolism of ophthalmic timolol: new aspects of an old drug.
Volotinen M; Hakkola J; Pelkonen O; Vapaatalo H; Mäenpää J
Basic Clin Pharmacol Toxicol; 2011 May; 108(5):297-303. PubMed ID: 21385322
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacology and pharmacogenetics of prostaglandin analogues in glaucoma.
Zhou L; Zhan W; Wei X
Front Pharmacol; 2022; 13():1015338. PubMed ID: 36313286
[TBL] [Abstract][Full Text] [Related]
4. Progress toward personalized medicine for glaucoma.
Moroi SE; Raoof DA; Reed DM; Zöllner S; Qin Z; Richards JE
Expert Rev Ophthalmol; 2009 Apr; 4(2):145-161. PubMed ID: 23914252
[TBL] [Abstract][Full Text] [Related]
5. Genetic diversity and medicinal drug response in eye care.
Shastry BS
Graefes Arch Clin Exp Ophthalmol; 2010 Aug; 248(8):1057-61. PubMed ID: 20204657
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetics - getting closer.
Macdonald IM
Open Ophthalmol J; 2009 Sep; 3():46-9. PubMed ID: 19816587
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics of beta-blockers.
Shin J; Johnson JA
Pharmacotherapy; 2007 Jun; 27(6):874-87. PubMed ID: 17542770
[TBL] [Abstract][Full Text] [Related]
8. A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy.
Denis P; Lafuma A; Khoshnood B; Mimaud V; Berdeaux G
Curr Med Res Opin; 2007 Mar; 23(3):601-8. PubMed ID: 17355741
[TBL] [Abstract][Full Text] [Related]
9. [Adverse effects of local use of beta-blockaders in glaucoma. A literature review and a survey of reports to the adverse drug reaction authority 1986-95].
Nygaard HA; Høvding G
Tidsskr Nor Laegeforen; 1997 May; 117(14):2019-21. PubMed ID: 9235677
[TBL] [Abstract][Full Text] [Related]
10. Polymorphism of the beta-2 adrenoceptor and IOP lowering potency of topical timolol in healthy subjects.
Fuchsjager-Mayrl G; Markovic O; Losert D; Lucas T; Wachek V; Muller M; Schmetterer L
Mol Vis; 2005 Sep; 11():811-5. PubMed ID: 16205624
[TBL] [Abstract][Full Text] [Related]
11. Influence of beta-2 adrenergic receptor gene polymorphism on the hemodynamic response to propranolol in patients with cirrhosis.
Turnes J; Hernández-Guerra M; Abraldes JG; Bellot P; Oliva R; García-Pagán JC; Bosch J
Hepatology; 2006 Jan; 43(1):34-41. PubMed ID: 16374847
[TBL] [Abstract][Full Text] [Related]
12. The lack of efficacy of topical beta-blockers, timolol and betaxolol on intraocular pressure in Nigerian healthy volunteers.
Olateju SO; Ajayi AA
Eye (Lond); 1999 Dec; 13 ( Pt 6)():758-63. PubMed ID: 10707140
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and systemic side-effects of topical 0.5% timolol aqueous solution and 0.1% timolol hydrogel.
Uusitalo H; Niño J; Tahvanainen K; Turjanmaa V; Ropo A; Tuominen J; Kähönen M
Acta Ophthalmol Scand; 2005 Dec; 83(6):723-8. PubMed ID: 16396651
[TBL] [Abstract][Full Text] [Related]
14. Polymorphic variants of the beta2-adrenergic receptor (ADRB2) gene and ADRB2-related propanolol-induced dyslipidemia in the Colombian population.
Isaza C; Henao J; Ramirez E; Cuesta F; Cacabelos R
Methods Find Exp Clin Pharmacol; 2005 May; 27(4):237-44. PubMed ID: 16082424
[TBL] [Abstract][Full Text] [Related]
15. The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization.
Dishy V; Sofowora GG; Xie HG; Kim RB; Byrne DW; Stein CM; Wood AJ
N Engl J Med; 2001 Oct; 345(14):1030-5. PubMed ID: 11586955
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
